linjc16/ctgov huggingface dataset:
Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys During Liver Transplant by Measuring Some Physiological Substances in Blood and Urines

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to verify any existing relationship between urinary parameters (such as excretion of sodium, chlorine, urinary partial CO2 pressure [PuCO2]) and general volemic indicators (such as PiCCO, ScvO2, O2 delivery) during liver transplant.

Official Title
-----------------
Evaluation of Sodium Urinary Excretion, Chlorine Urinary Excretion, Urinary Partial CO2 Pressure as Renal Perfusion Indicators During Liver Transplant. Comparison With Other Polemic State Indicators (Such as PiCCO, ScvO2, O2 Delivery).

Conditions
-----------------
Hypovolemia During Liver Transplantation, Renal Hypoperfusion During Liver Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: surgery for liver transplantation age 18-75 ASA class I-III Exclusion Criteria: age above 75 or under 18 ASA class IV pre-existing renal failure pregnant patients patients unable to give written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of hemodynamic indicators (PiCCO, ScvO2, O2-delivery) and three urinary analytes (sodium, chloride, CO2 partial pressure) |  | During the stay of the patient in the operating room (in average 8 hours) and the subsequent stay in the post-surgery intensive care unit (in average 5 days) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypovolemia, renal hypoperfusion, liver transplantation, sodium, chloride, PuCO2, ScvO2, PiCCO, O2-delivery, hemodynamic indexes
Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients

Official Title
-----------------
A 12-Week Randomized, Double-Blinded Study to Evaluate the Effects of Daily Oral Doses of BMS-741672 in Drug-Naive Type 2 Diabetic Patients

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: CCR2 Antagonist
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10% Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL BMI ≤ 40 kg/m2 Exclusion Criteria: Active tuberculosis Symptoms of poorly controlled diabetes History of diabetic ketoacidosis Significant cardiovascular history or gastrointestinal disorders History of unstable or rapidly progressing renal disease Active liver disease and/or significant abnormal liver function Abnormal chest x-ray at screening indicative of tuberculosis or other infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A1<br> | Drug: CCR2 Antagonist<br>* Tablets, Oral, 50 mg, once daily, 12 weeks<br>* Other names: BMS-741672;|
| Placebo Comparator: A2<br> | Drug: Placebo<br>* Tablets, Oral, 0mg, once daily, 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c |  | after 12 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured |  | throughout the 12 weeks of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, NOS
Endometriosis and Risk of Miscarriage

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the rate of miscarriage at first spontaneous pregnancy among women with endometriosis with the rate of miscarriage at first spontaneous pregnancy among women without endometriosis.

Detailed Description
-----------------
All women followed up for a surgical or sonographic diagnosis of endometriosis in 11 italian referral Centres for the treatment of endometriosis completed a questionnaire regarding their previous pregnancies. The same questionnaire was completed by women, attending a routine gynecologic visit, in whom surgery or vaginal examination and pelvic ultrasonography excluded endometriosis.

Official Title
-----------------
Impact of Endometriosis on the Risk of Miscarriage in Spontaneous Pregnancy: a Multicentric Italian Study

Conditions
-----------------
Endometriosis, Miscarriage

Intervention / Treatment
-----------------
* Other: Survey on first pregnancy after endometriosis diagnosis
* Other: Survey on first pregnancy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30 to 50 years old women with at least one previous spontaneous pregnancy with surgical or clinical/sonographic diagnosis of endometriosis or in whom surgical or clinical/sonographic evaluation ruled out endometriosis Exclusion Criteria: Pregnancy achieved by Assisted Reproductive technology Biochemical pregnancy Non corrected uterine malformation, poliabortivity, lupus like anticoagulant

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| endometriosis<br>Survey on first pregnancy after endometriosis diagnosis | Other: Survey on first pregnancy after endometriosis diagnosis<br>* rate of miscarriage was noted<br>|
| non endometriosis<br>Survey on first pregnancy | Other: Survey on first pregnancy<br>* rate of miscarriage was noted<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of miscarriage | comparison of rate of miscarriage in the two groups | 2 years |
Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

Official Title
-----------------
Tolerability, Safety, and Pharmacokinetics of Repeated Sublingual Doses of Lobeline

Conditions
-----------------
Methamphetamine Dependence

Intervention / Treatment
-----------------
* Drug: Lobeline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be able to provide written informed consent Must have a body mass index between 18 and 30 Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis Must have a negative drug test at screening and admission If female of child bearing potential, must agree to use birth control Exclusion Criteria: Please contact the site for more information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lobeline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerability |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  |  | 
| Pharmacokinetic parameters |  |  | 
| Cardiovascular responses |  |  | 
| Psychological effects of lobeline |  |  |
Brain Computer Interface for Communication in ICU: a Feasibility Study

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to evaluate the usability of a system to assist verbal communication based on BCI system using the P300 wave in patients with tetraplegia who can no longer communicate because of severe engine damage (tetraplegia) and respiratory damage requiring invasive mechanical ventilation (intubation or tracheostomy) preventing verbal communication.

Official Title
-----------------
A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU

Conditions
-----------------
Tetraplegia, Guillain-Barre Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted in the ICU Quadriplegic and requiring mechanical ventilation (tracheostomy) 24/24h Exclusion Criteria: Acute respiratory failure. Visual disorder Cognitive disorder Illiterate patient Mother tongue other than french

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
brain computer interface, P3Speller, P300, Event Related potential, tetraplegia, Guillain barre syndrome, Feasibility, Speed of spelling, Accuracy
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

Study Overview
=================
Brief Summary
-----------------
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages of 3-16 who are failing or intolerant of their current antiretroviral regimen and who are unable to swallow Sustiva capsules.

Official Title
-----------------
Canadian Sustiva Oral Liquid Expanded Access Program: An Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP266)

Conditions
-----------------
HIV Infection

Intervention / Treatment
-----------------
* Drug: Efavirenz


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 3-16 years of age Anti-retroviral naive or experienced Failing or intolerant to current anti-retroviral (ARV) regimen Limited available viable therapeutic options Inability to take capsules/tablets Exclusion Criteria: Weighs less than 10 kg Failure on or concomitant use of other non-nucleoside reverse transcriptase inhibitors (NNRTIs) An active AIDS-defining opportunistic infection or disease More than two episodes of moderate to severe diarrhea or vomiting lasting more than four days within the past three months

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis

Study Overview
=================
Brief Summary
-----------------
The investigators performed a retrospective, single-center observational study, and the participants with acute fulminant myocarditis were included.Then, the investigator analyzed the risk factors of in-hospital death in these participants with acute fulminant myocarditis.

Official Title
-----------------
Risk Factors Influenced Prognosis of Acute Fulminant Myocarditis by Analyzing Clinical Characteristics and Complications, Laboratory Findings, Treatments, and Electrocardiographic and Echocardiographic Data.

Conditions
-----------------
Viral Myocarditis, Cardio-Renal Syndrome, Risk Factor, Cardiovascular

Intervention / Treatment
-----------------
* Other: prognosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of acute fulminant myocarditis Exclusion Criteria: chronic renal dysfunction refuse medical treatments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-survivor group<br> | Other: prognosis<br>* The participants were divided into two groups based on survival at their hospital discharge.<br>|
| survivor group<br> | Other: prognosis<br>* The participants were divided into two groups based on survival at their hospital discharge.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal Impairment Influence Prognosis of Acute Fulminant Myocarditis |  | 2017-01-30 |
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.

Official Title
-----------------
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment

Conditions
-----------------
Hepatitis C

Intervention / Treatment
-----------------
* Drug: MP-424
* Drug: Ribavirin
* Drug: Peginterferon Alfa-2b


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Genotype 1, chronic hepatitis C Non-responders (patient who did not respond to previous treatment) Able and willing to follow contraception requirements Exclusion Criteria: Cirrhosis of the liver or hepatic failure Hepatitis B surface antigen-positive or HIV antibodies-positive History of, or concurrent hepatocellular carcinoma History of, or concurrent depression, schizophrenia; or suicide attempt in the past Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MP-424<br> | Drug: MP-424<br>* 750 mg every 8 hours for 12 weeks<br>* Other names: Telaprevir;Drug: Ribavirin<br>* 600 - 1000 mg/day based on body weight for 24 weeks<br>Drug: Peginterferon Alfa-2b<br>* 1.5 mcg/kg/week for 24 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) |  | After 24 weeks of follow-up |
Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Study Overview
=================
Brief Summary
-----------------
This study have two aims, the first is to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database the second is to provide a more accurate staging for Siewert type II AEG patients.

Official Title
-----------------
Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Conditions
-----------------
Adenocarcinoma of the Esophagogastric Junction

Intervention / Treatment
-----------------
* Procedure: esophagogastric junction cancer surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed T1-4aN0-3M0 stage after surgery after a pathological examination of the LNs.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: esophagogastric junction cancer surgery|esophagogastric junction cancer surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | the time from disease diagnosis to death from any cause | 5-year overall survival | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophagogastric junction, total examined lymph nodes, staging
Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases

Study Overview
=================
Brief Summary
-----------------
To understand the HPV infection status and subtype distribution of patients, and to study the protective effect of prophylactic HPV vaccination on the recurrence of HPV related diseases after treatment through a prospective cohort study. To provide data support for the primary prevention of HPV related diseases in Chinese women after treatment, and to analyze the related factors of HPV related disease recurrence and HPV continuous positive.

Official Title
-----------------
Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases

Conditions
-----------------
HPV Vaccination、HPV Related Diseases、Protective Efficacy

Intervention / Treatment
-----------------
* Biological: HPV vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Women aged 18-45, of childbearing age or before perimenopause (patients without pregnancy plan within two years); 2. Patients diagnosed as condyloma acuminatum, vaginal intraepithelial lesions (high-grade and low-grade lesions), cervical intraepithelial lesions (high-grade and low-grade lesions), vulvar intraepithelial lesions (high-grade and low-grade lesions), cervical cancer (IA1-IIA2 stage) and treated within 3 months; 3. No surgical contraindications such as severe center of heart, lung and other organ dysfunction and abnormal hemagglutination; 4. Fully know the treatment method, sign informed consent, and actively cooperate with follow-up. Exclusion Criteria: 1. Participating in other clinical trials; 2. Use immunoglobulin or blood products within 3 months before vaccination; 3. Hypersensitivity to vaccine active ingredients or any dressing ingredients; 4. Acute stage of moderate and severe diseases; 5. Acute stage of severe immune deficiency diseases and autoimmune diseases; 6. Pregnant women and lactating patients; 7. Patients with planned pregnancy within 2 years; 8. Less than 18 years old and more than 45 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Group<br>HPV vaccine group | Biological: HPV vaccine<br>* Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes<br>|
| Control group<br>non HPV vaccine group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence | If The lesions were found again more than 6 months after operation (pathological diagnosis) | 6 months after operation | 
| Persistent HPV infection | At least 12 months apart, cervical vaginal / external genital swabs or tissue biopsies were taken for 2 or more consecutive times, and HPV detection and analysis showed that the same HPV type was positive | At least 12 months |